SWAN Genomics
Unlocking the future of genomics with ultra-scalable, affordable, and precise single-molecule sequencing for healthcare and research.
At a glance
-
Development stage
Proof-of-concept
-
Investment stage
Pre-Seed
-
UNSW affiliation
Spinout - staff led
-
Technology readiness level
TRL-4
Team with decades of success in commercialising DNA sequencing technologies including in ABI, Illumina, PacBio, and Omniome tackling the AUD100 billion+ global genomics market.
Swan Genomics’ novel single-molecule DNA sequencing platform delivers scalability, affordability, and precision.
Backed by industry veterans and targeting an AUD100 billion+ market, its technology enables population-scale genomics to unlock the full potential of genomic insights in healthcare and beyond.
-
Swan Genomics' single-molecule sequencing platform overcomes the limitations of existing short- and long-read technologies. It uses proprietary nanoscale optical antennae to amplify the fluorescent signal of a single molecule by 1,000-fold, allowing us to isolate and identify individual nucleotides in real time.
Ultra‑cheap chemical synthesis will allow long- and short-read sequencing at unprecedented scale, accuracy and cost-efficiency. Swan Genomics enables genomic insights at population scale for better diagnostics, personalised medicine, and biotechnology.
-
- Current DNA sequencing technologies (both short-read and long-read) suffer trade-offs between cost, scalability, accuracy and read length.
- These constraints hinder widespread adoption, prevent population-scale genomics, and slow progress in healthcare and research, leaving critical genetic insights inaccessible or unaffordable for many applications and regions.
- World-class leadership team: 25+ patents,100+ publications, 300+ products, 15+ companies exited
-
- Healthcare
- Agriculture
- Defence
- Biotechnology
-
- AUD8 million pre-seed invested from Australia, US and NZ
- Partnerships with Fonterra and the Australian Genome Research Facility
Discover more UNSW spinouts
Search our catalogue of active spinouts and tech for license.